From: The “Great Debate” at Immunotherapy Bridge 2022, Naples, November 30th–December 1st, 2022
ACT approach | Challenges |
---|---|
ACT with tumor-infiltrating lymphocytes | Limited success rates |
Most expanded TILs are irrelevant for tumor antigens | |
Prepared tumor-specific TILs have questionable tumor antigen specificity | |
TIL manufacturing process too long for patients to wait | |
Long TIL manufacturing process leads T cell exhaustion | |
Immune suppression in the TME limits TIL functions | |
High risk of adverse events from treatment and co-administered IL-2 | |
CAR T cells/TCR-T cells | Requires suitable antigen targets that are not often available or adequately tumor-specific |
Limited success across attempts with a variety of tumor antigens | |
Limited data on use of improved CARs with integrated controls | |
Difficulties in getting cell therapies to successfully traffic into solid tumor sites | |
Financial toxicity to the patient due to high costs of therapy, especially for underserved populations and for underinsured or uninsured patients | |
Increased risk of ”on-target off-tumor” toxicity |